The prodrug approach: a successful tool for improving drug solubility

DH Jornada, GF dos Santos Fernandes, DE Chiba… - Molecules, 2015 - mdpi.com
Prodrug design is a widely known molecular modification strategy that aims to optimize the
physicochemical and pharmacological properties of drugs to improve their solubility and …

An updated overview on therapeutic drug monitoring of recent antiepileptic drugs

S Jacob, AB Nair - Drugs in R&D, 2016 - Springer
Given the distinctive characteristics of both epilepsy and antiepileptic drugs (AEDs),
therapeutic drug monitoring (TDM) can make a significant contribution to the field of …

Epilepsy treatment in adults and adolescents: expert opinion, 2016

JJ Shih, JB Whitlock, N Chimato, E Vargas… - Epilepsy & Behavior, 2017 - Elsevier
Introduction: There are over twenty anti-seizure medications and anti-seizure devices
available commercially in the United States. The multitude of treatment options for seizures …

Eslicarbazepine acetate: a new improvement on a classic drug family for the treatment of partial-onset seizures

GL Galiana, AC Gauthier, RH Mattson - Drugs in R&D, 2017 - Springer
Eslicarbazepine acetate is a new anti-epileptic drug belonging to the dibenzazepine
carboxamide family that is currently approved as adjunctive therapy and monotherapy for …

Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

A Strzelczyk, KM Klein, LM Willems… - Expert review of …, 2016 - Taylor & Francis
Brivaracetam is the latest approved antiepileptic drug in focal epilepsy and exhibits high
affinity as SV2A-ligand. More than two thousand patients have received brivaracetam within …

Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents

S Schubert-Bast, LM Willems, G Kurlemann, S Knake… - Epilepsy & Behavior, 2018 - Elsevier
Introduction This multicenter, retrospective study aimed to evaluate the efficiency, retention,
safety, and tolerability of brivaracetam (BRV) in children and adolescents with focal epilepsy …

Comparing safety and efficacy of “third-generation” antiepileptic drugs: long-term extension and post-marketing treatment

CS Kwok, EL Johnson, GL Krauss - CNS drugs, 2017 - Springer
Four “third-generation” antiepileptic drugs (AEDs) were approved for adjunctive treatment of
refractory focal onset seizures during the past 10 years. Long-term efficacy and safety of the …

Decarboxylative acetoxylation of aliphatic carboxylic acids

S Senaweera, KC Cartwright… - The Journal of Organic …, 2019 - ACS Publications
Organic molecules bearing acetoxy moieties are important functionalities in natural
products, drugs, and agricultural chemicals. Synthesis of such molecules via transition metal …

In vitro and in vivo anti‐epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2‐related self‐limited epilepsy

L Monni, L Kraus, M Dipper‐Wawra… - British Journal of …, 2022 - Wiley Online Library
Background and Purpose The KCNQ2 gene encodes for the Kv7. 2 subunit of non‐
inactivating potassium channels. KCNQ2‐related diseases range from autosomal dominant …

The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience

S Bauer, LM Willems, E Paule… - Therapeutic …, 2017 - journals.sagepub.com
Lacosamide (LCM) is approved for anticonvulsive treatment in focal epilepsy and exhibits its
function through the slow inactivation of voltage-gated sodium channels (VGSCs). LCM …